Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024

2024-03-07

财报

CARLSBAD, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2023, before the market opens on Monday, March 18, 2024. John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 8:30 AM ET (5:30 AM PT). Interested parties may access the conference call by dialing (201) 389-0918 (U.S.) or (877) 407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com. A replay of the conference call will be available until Monday, April 1, 2024, at 11:59 PM ET (8:59 PM PT). Interested parties may access the replay of the conference call by dialing (201) 612-7415 (U.S.) or (877) 660-6853 (international) using passcode 13743861. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes. About Exagen Inc. Exagen is a leading provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision making with the goal of improving patients’ clinical outcomes. Exagen is located in San Diego County, California. For more information, please visit Exagen.com or follow @ExagenInc on X (formerly known as Twitter). Contact: Ryan Douglas Exagen Inc. ir@exagen.com 760.560.1525

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构